Stocks / HALO / Total Debt

Halozyme Therapeutics, Inc. Total Debt 2009–2025

Halozyme Therapeutics, Inc. reported $2.14B of total debt (short- plus long-term borrowings) for fiscal 2025. That was 42.3% higher than fiscal 2024.

Latest filed value
$2.14B
One-year change
+42.3%
Change since 2020
Latest period end
2025
Halozyme Therapeutics, Inc. Total Debt history from 2009 to 2025FY 2009: 0FY 2010: 0FY 2011: 0FY 2012: 29661680FY 2013: 49772000FY 2014: 49860000FY 2015: 27971000FY 2016: 199228000FY 2017: 125140000FY 2018: 34874000FY 2019: 383045000FY 2020: 0FY 2021: 787255000FY 2022: 1506100000FY 2023: 1499248000FY 2024: 1505798000FY 2025: 2142630000
Annual filed history. Hover chart points for raw values; the accessible table below is the source of record.
Fiscal yearTotal DebtChange (YoY)
FY 2025$2.14B+42.3%
FY 2024$1.51B+0.4%
FY 2023$1.50B-0.5%
FY 2022$1.51B+91.3%
FY 2021$787.25M
FY 2020$0-100.0%
FY 2019$383.05M+998.4%
FY 2018$34.87M-72.1%
FY 2017$125.14M-37.2%
FY 2016$199.23M+612.3%
FY 2015$27.97M-43.9%
FY 2014$49.86M+0.2%
FY 2013$49.77M+67.8%
FY 2012$29.66M
FY 2011$0
FY 2010$0
FY 2009$0

Source: Halozyme Therapeutics, Inc. SEC filings — balance sheet (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open HALO 10-K filings at SEC EDGAR · Methodology · Download CSV.

How to read this history

Halozyme Therapeutics, Inc. reported $2.14B of total debt (short- plus long-term borrowings) for fiscal 2025. That was 42.3% higher than fiscal 2024. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.

Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.

See the full picture for Halozyme Therapeutics, Inc.

Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.

Open the interactive view — free

Halozyme Therapeutics, Inc. — frequently asked questions

What is Halozyme Therapeutics, Inc.'s total debt (short- plus long-term borrowings)?

Halozyme Therapeutics, Inc. (HALO) reported total debt (short- plus long-term borrowings) of $2.14B for fiscal year 2025, per its SEC filings.

Where does this data come from?

Figures are computed from Halozyme Therapeutics, Inc.'s official SEC filings (balance sheet (10-K)), refreshed nightly. Not investment advice.

More HALO financial history

Full HALO fundamentals page → · Analyze total debt (short- plus long-term borrowings) with a free tool → · All 1,500+ companies →